Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

Autor: Jeffrey Huang, Sumanta Pal, Tanya Dorff, Owen T M Chan, Hideki Furuya, Ian Pagano, Yosuke Hirasawa, Jared Acoba, David Tamura, Minlu Zhang, Rebecca Waitz, Abhilash Dhal, Winston Haynes, John Shon, Mark Scholz, Charles Rosser

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)

Background Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metas

Externí odkaz: https://doaj.org/article/777a359f9d2d4d038339263ff0f9ad51

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy

Autor: Joanne Weidhaas, Nicholas Marco, Aaron W Scheffler, Anusha Kalbasi, Kirk Wilenius, Emily Rietdorf, Jaya Gill, Mara Heilig, Caroline Desler, Robert K Chin, Tania Kaprealian, Susan McCloskey, Ann Raldow, Naga P Raja, Santosh Kesari, Jose Carrillo, Alexandra Drakaki, Mark Scholz, Donatello Telesca

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Journal for immunotherapy of cancer, vol 10, iss 2

BackgroundThere is great interest in finding ways to identify patients who will develop toxicity to cancer therapies. This has become especially pressing in the era of immune therapy, where toxicity can be long-lasting and life-altering, and primaril

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057217867d2e1f09df31d2eaff05f0aa
https://doi.org/10.1136/jitc-2021-003625

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Autor: Stacy Wentworth, Robyn Vera, Richard G. Stock, Ed Weber, Mira Keyes, Brian J. Moran, Michael J. Zelefsky, W. Robert Lee, Peter D. Grimm, Katsuto Shinohara, Stefann Machtens, Jeremy Millar, Jason Wong, Stephen E.M. Langley, Ignace Billiet, Adam P. Dicker, Patrick A. Kupelian, Steven J. Frank, Jos Immerzeel, Gregory S. Merrick, Anthony L. Zietman, Jyoti Mayadev, Mack Roach, David Bostwick, Mark Scholz

Publikováno v: BJU International. 109:22-29

What's known on the subject? and What does the study add? Very few comparative studies to date evaluate the results of treatment options for prostate cancer using the most sensitive measurement tools. PSA has been identified as the most sensitive too

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e45f3576770fd82a894e3ecb3e00a770
https://doi.org/10.1111/j.1464-410x.2011.10827.x

Invasion of the Prostate Snatchers : An Essential Guide to Managing Prostate Cancer for Patients and Their Families

Autor: Mark Scholz, Ralph Blum

Every year almost a quarter of a million confused and frightened American men are tossed into a prostate cancer cauldron stirred by salespeople representing a multibillion-dollar industry. In this flourishing business, the radical prostatectomy is st

RE: RECOVERY OF SPONTANEOUS ERECTILE FUNCTION AFTER NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY WITH AND WITHOUT EARLY INTRACAVERNOUS INJECTIONS OF ALPROSTADIL

Autor: Mark Scholz, Stephen Strum

Publikováno v: Journal of Urology. 161:1914-1915

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86d34054348e100bc99656a458ed7cf3
https://doi.org/10.1016/s0022-5347(05)68849-0